CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medication firm reworking the drug discovery course of by combining modern computational and experimental applied sciences, introduced as we speak the pricing of an underwritten public providing of 11,320,755 shares of its frequent inventory at a public providing value of $26.50 per share. Relay Therapeutics additionally granted the underwriters a 30-day choice to buy as much as a further 1,698,113 shares of its frequent inventory. The gross proceeds from the providing, earlier than deducting underwriting reductions and commissions and providing bills, are anticipated to be roughly $300.0 million, excluding any train of the underwriters’ choice to buy further shares. All of the shares within the providing are to be bought by Relay Therapeutics.
Goldman Sachs & Co. LLC, J.P. Morgan, and Cowen are appearing as joint book-running managers for the providing. BofA Securities can be appearing as a book-running supervisor. The providing is predicted to shut on or about September 15, 2022, topic to customary closing situations.
The shares of frequent inventory are being provided by Relay Therapeutics pursuant to an efficient shelf registration assertion that was beforehand filed with the U.S. Securities and Exchange Commission (SEC). A preliminary prospectus complement and accompanying prospectus referring to and describing the phrases of the providing was filed with the SEC on September 12, 2022. The remaining prospectus complement and accompanying prospectus referring to the providing can be filed with the SEC and could also be obtained, when accessible, from Goldman Sachs & Co. LLC, by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by phone at (866) 471-2526, or by e-mail at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone at 866-803-9204 or by e-mail at [email protected]; Cowen and Company, LLC, Attn: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by e-mail at [email protected], or by phone at (833) 297-2926; or BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, third Floor, Charlotte, NC 28255-0001, by phone at (800) 299-1322 or by e-mail at [email protected]; or by accessing the SEC’s web site at www.sec.gov.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of these securities in any state or jurisdiction by which such supply, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medication firm reworking the drug discovery course of by combining modern computational and experimental applied sciences with the aim of bringing life-changing therapies to sufferers. As the primary of a brand new breed of biotech created on the intersection of disparate applied sciences, Relay Therapeutics goals to push the boundaries of what’s potential in drug discovery. Its Dynamo™ platform integrates an array of modern computational and experimental approaches designed to drug protein targets which have beforehand been intractable. Relay Therapeutics’ preliminary focus is on enhancing small molecule therapeutic discovery in focused oncology and genetic illness indications.
Cautionary Note Regarding Forward-Looking Statements
This press launch accommodates forward-looking statements throughout the that means of the Private Securities Litigation Reform Act of 1995, as amended, together with, with out limitation, statements relating to the closing of Relay’s anticipated public providing. The phrases “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and comparable expressions are supposed to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases.
Any forward-looking statements on this press launch, such because the supposed providing phrases, are primarily based on administration’s present expectations and beliefs and are topic to a quantity of dangers, uncertainties and vital elements which will trigger precise occasions or outcomes to vary materially from these expressed or implied by any forward-looking statements contained on this press launch, together with, with out limitation, uncertainties associated to market situations and the completion of the general public providing on the anticipated phrases or in any respect. These and different dangers and uncertainties are described in larger element within the part entitled “Risk Factors” in Relay’s most up-to-date annual report on Form 10-Ok and quarterly report on Form 10-Q filed with the SEC, in addition to discussions of potential dangers, uncertainties, and different vital elements in Relay’s different filings with the SEC, together with these contained or included by reference within the preliminary prospectus complement and accompanying prospectus associated to the general public providing filed with the SEC. Any forward-looking statements contained on this press launch characterize Relay’s views solely as of the date hereof and shouldn’t be relied upon as representing its views as of any subsequent date. Relay explicitly disclaims any obligation to replace any forward-looking statements, besides as required by regulation.
Contact:
Caroline Glen
617-370-8837
[email protected]
Media:
Dan Budwick
1AB
973-271-6085
[email protected]
